J&J beats Wall Street estimates on strength in medicines unit

• Tremfya sales surged 72.5% to $2 billion, significantly beating estimates of $1.74 billion, as J&J works to offset revenue losses from patent-expired Stelara
• Abiomed heart pump sales fell 2% year-over-year after a UK study raised safety concerns, down from 14% growth in the first quarter
• J&J raised its full-year sales forecast to $101.1 billion (from $100.8 billion) and increased its adjusted earnings outlook

J&J Beats Q2 Estimates on Strong Pharmaceutical Performance

Johnson & Johnson exceeded Wall Street expectations for second-quarter 2024, reporting sales of $25.31 billion, up 6.6% year-over-year and above the $25.05 billion analyst estimate. Adjusted earnings reached $2.90 per share, prompting the company to raise its full-year outlook to approximately $101.1 billion in sales (from $100.8 billion previously) and increased adjusted earnings guidance.

Key Performance Drivers:

The pharmaceutical unit led growth with $16.38 billion in quarterly sales, surpassing the $16.1 billion estimate. Tremfya, treating psoriasis and inflammatory bowel disease, achieved exceptional growth of 72.5% to $2 billion (versus $1.74 billion expected). This drug is strategically important as J&J offsets declining revenue from Stelara, which lost patent protection. Cancer treatment Darzalex generated $4.2 billion, meeting analyst expectations.

Challenges:

The medical technology unit reported $8.93 billion in sales, slightly missing estimates. Abiomed's heart pump business declined 2% year-over-year, a significant slowdown from 14% growth in Q1. CFO Joseph Wolk attributed weakness to a UK study questioning Impella pump efficacy in certain high-risk procedures. Management expects recovery with new data supporting the pumps' utility anticipated in early 2025.

Market Implications:

J&J's diversified portfolio of 28 platforms generating at least $1 billion annually provides resilience against single-product challenges. The strong pharmaceutical performance, particularly Tremfya's momentum, demonstrates successful product transition strategy. However, investors should monitor Abiomed's recovery trajectory and the impact of upcoming clinical data on the Impella franchise.